Top 50 Biotechnology Startup Investors (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
257 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
ARCH Venture Partners
VC Fund
|
158 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $8.4M–$230M |
|
OrbiMed
VC Fund
|
122 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$151M |
|
Alexandria Venture Investments
VC Fund
|
119 | United States, Canada, France | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$150M |
|
Sofinnova Partners
VC Fund
|
113 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Novo Holdings
VC Fund
|
105 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$135M |
|
Qiming Venture Partners
VC Fund
|
102 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
Bpifrance
VC Fund
|
89 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $726k–$34M |
|
Versant Ventures
VC Fund
|
89 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
F-Prime
VC Fund
|
88 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $9.2M–$165M |
|
Atlas Venture
VC Fund
|
85 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.5M–$115M |
|
RA Capital Management
VC Fund
|
83 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$240M |
|
New Enterprise Associates
VC Fund
|
83 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.4M–$103M |
|
Alumni Ventures
VC Fund
|
81 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$79M |
|
Khosla Ventures
VC Fund
|
77 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | $2M–$100M |
|
Polaris Partners
VC Fund
|
72 | United States, Ireland, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$107M |
|
Google Ventures
VC Fund
|
71 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Gaingels
VC Fund
|
71 | United States, Canada, Mexico | Seed, Series A, Series B | Software, Health Care, Artificial Intelligence | $1.1M–$100M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
71 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
M Ventures
VC Fund
|
70 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Third Rock Ventures
VC Fund
|
68 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
Novartis Venture Fund
VC Fund
|
68 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
5AM Ventures
VC Fund
|
68 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $13M–$120M |
|
MPM Capital
VC Fund
|
66 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$125M |
|
Innova Memphis
VC Fund
|
63 | United States, Argentina, United Kingdom | Seed, Pre-Seed | Health Care, Medical, Medical Device | $25k–$1.7M |
|
Forbion Capital Partners
VC Fund
|
63 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
UK Innovation & Science Seed Fund
VC Fund
|
62 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $458k–$14M |
|
Lilly Asia Ventures
VC Fund
|
60 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$283M |
|
Andreessen Horowitz
VC Fund
|
58 | United States, United Kingdom, Brazil | Series A, Seed, Series B | Software, Information Technology, Artificial Intelligence | $1.6M–$112M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
57 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Pfizer Venture Investments
VC Fund
|
56 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$123M |
|
Canaan Partners
VC Fund
|
56 | United States, United Kingdom, Israel | Series A, Series B, Series C | Software, Biotechnology, Health Care | $5M–$75M |
|
HSG
VC Fund
|
56 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Scottish Enterprise
VC Fund
|
56 | United Kingdom, United States, Switzerland | Grant, Seed | Biotechnology, Software, Health Care | $119k–$4.3M |
|
Lux Capital
VC Fund
|
55 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.8M–$193M |
|
SR One
VC Fund
|
53 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$175M |
|
BioAdvance
VC Fund
|
51 | United States, Canada | Seed, Series A | Biotechnology, Health Care, Medical | $350k–$40M |
|
Eli Lilly
VC Fund
|
51 | United States, United Kingdom, Canada | Series A, Series B | Biotechnology, Health Care, Medical | $6.5M–$175M |
|
KdT Ventures
VC Fund
|
49 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Fifty Years
VC Fund
|
49 | United States, Germany, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Artificial Intelligence | $2M–$91M |
|
Omega Funds
VC Fund
|
48 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Parkwalk Advisors
VC Fund
|
47 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.1M–$46M |
|
Seventure Partners
VC Fund
|
47 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.1M–$65M |
|
Takeda Ventures
VC Fund
|
47 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
DCVC
VC Fund
|
47 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1.5M–$130M |
|
Sofinnova Investments
VC Fund
|
47 | United States, France, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $7.3M–$150M |
|
Oxford Science Enterprises
VC Fund
|
46 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
The Column Group
VC Fund
|
46 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.2M–$120M |
|
EQT Life Sciences
VC Fund
|
46 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
Connecticut Innovations
VC Fund
|
46 | United States, Israel, Canada | Seed, Series A | Health Care, Biotechnology, Software | $300k–$25M |
| Access all 17645 investors in Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 412
- Round size: Series A $8.4M–$213M; Series B $14M–$230M; Series C $15M–$175M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Synchron — The endovascular brain computer interface.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- HI-Bio — HI-Bio leverages human genetic and immunological insights to deliver targeted, effective medicines to patients with immune-mediated diseases.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 611
- Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- MDClone — The MDClone ADAMS Platform is a self-service, data analytics environment powering healthcare collaboration, innovation, and data-driven projects.
- Beijing Tianxing — Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, France
Investor stats
- Total investments: 262
- Round size: Seed $2M–$31M; Series A $12M–$101M; Series B $25M–$150M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
- Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.
- CREATE Medicines — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 317
- Round size: Series A $6.6M–$65M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 350
- Round size: Series A $9M–$125M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Verana Health — Verana Health is assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 803
- Round size: Series A $5M–$68M; Series B $9.4M–$100M; Series C $14M–$134M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Chuman — Chuman is a UGC Pan-Secondary Creation Community, providing creative platforms and studios for comic creators, and providing IP incubation and resource docking services. Users can quickly generate a lot of content through third-party or official materials, and can make friends, transactions and other activities within the community through thecreation, while the APP also supports the dialogue novel reading function.
- Wholee — Wholee is a member-only zero-markup store.
- Zeen Health — Zeen Health is a digital therapeutics company that provides mental health services. Zeen Health was founded in 2019 and was headquartered in Shenzhen, China.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1268
- Round size: Seed $726k–$6.5M; Series A $2.7M–$34M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
- Probabl — Open Source Commons for AI, Machine Learning, and Data Science.
- Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 287
- Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 433
- Round size: Series A $9.2M–$87M; Series B $15M–$112M; Series C $22M–$165M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
- Logixboard — The best way for freight forwarders to give customers shipment visibility.
- Orchard Therapeutics — Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 431
- Round size: Series A $3.5M–$75M; Series B $8M–$115M; Series C $6M–$95M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
- K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
- Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 478
- Round size: Series B $26M–$151M; Series C $44M–$183M; Post-IPO Equity $35M–$240M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1581
- Round size: Series A $5.4M–$60M; Series B $10M–$77M; Series C $14M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- IonQ — Working to build the world's best quantum computers to solve the world's most complex problems
- Spyglass Ophthalmics — A vision towards a higher quality of life!
- Xenon Pharmaceuticals — A leading neuroscience company forging new paths for those living with neurological and psychiatric disorders.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 1791
- Round size: Seed $1.5M–$10M; Series A $5.5M–$37M; Series B $11M–$79M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- NextDroid — NextDroid - We're Doing Something Different
- Enact — Enact is a leading solar energy and solar software company serving homeowners, businesses, and installers. Get a free quote or request a demo today!
- ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1150
- Round size: Seed $2M–$25M; Series A $5.5M–$45M; Series B $10M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $557M in 2022
Portfolio highlights
- eASIC — eASIC, a fabless semiconductor company, manufactures eASIC platforms that reduce the cost of ownership and time to production of customized silicon devices. It develops Nextreme family of devices that reduce development cost and turn-around times compared to standard cell ASICs, while reducing power consumption and unit cost for designs,Nextreme-3, a fourth generation eASIC platform, and Nextreme-2, a third generation eASIC platform. eASIC also provides easicopy ASIC that provides OEMs with a path from Nextreme-3, Nextreme-2, or Nextreme devices to a cell-based easicopy ASIC, which thereby helps OEMs reduce device cost and power consumption further, or increase performance, and eZ-IP alliance program to bring a wealth of verified eASIC-ready IP cores to help customers get to market faster. Its products are used in various applications that span from wireless infrastructure to consumer handheld devices. eASIC serves customers worldwide. Zvi Or-Bach founded eASIC in 1999, with its headquarters in Santa Clara in California with additional offices worldwide.
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 461
- Round size: Series A $4.5M–$83M; Series B $7M–$107M; Series C $10M–$100M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $182M in 1998
Portfolio highlights
- Living Proof — Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely newmolecules and breakthrough technologies for results you can see from across the room.
- ReadyForZero — ReadyForZero creates online financial software that helps people tackle any debt and protect their credit - automatically. It's not a "debt negotiation" or "debt settlement" service. The company was co-founded by Rod Ebrahimi and Ignacio Thayer as part of Y Combinator in the Summer of 2010. ReadyForZero is aventure-backed technical product team based in San Francisco.
- Seamless Receipts — Extensive selection of high-quality domain names. Knowledgeable, friendly customer support.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1110
- Round size: Seed $1.1M–$16M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Cambridge Epigenetix — CEGX develops products for academia and industry, democratizing step-changes in accuracy and cost.
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Mexico
Investor stats
- Total investments: 1006
- Round size: Seed $1.1M–$8.1M; Series A $5M–$40M; Series B $16M–$100M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- BQP — BosonQ Psi Pvt. Ltd. (BQP) is a state-of-the-art SaaS-based enterprise software venture leveraging the power of Quantum computing to speed up virtual simulations of Multiphysics and Computer-Aided Engineering (CAE) nature. BosonQ Psi is at the forefront of this quantum revolution. Our vision is to become the premier multiphysics simulation softwareusing quantum computing. Our world-class software suite will include computational science fields of fluid dynamics, structural dynamics, thermal, chemical, and aeroacoustics. With such an innovative product, we will revolutionize the computational world by enabling high-fidelity simulations that are impossible to solve with current computing technology. Further, this product will aid aerospace, automotive, energy, manufacturing, biotechnology, civil engineering, and astrophysics industries in saving millions of dollars by reducing long turnaround times of simulations used in the design process and give higher accuracy to make significant design changes for giving rise to the next generation of an electric car, eVTOL, skyscraper, or even Mars Rover.The possibility to harness the power of quantum computers is endless, and we at BQP thrive on pushing the boundaries of quantum computing technologies to serve our clients. We have made it our mission to bring these possibilities into the hands of every person - from a researcher to a scientist, from a professor to a student. Our name, BosonQ Psi, pays tribute to the great Indian physicist Dr. Satyendra Nath Bose, after whose name the elementary particle in quantum mechanics, Boson, was named and further incorporates the fundamental quantity that describes the state of the quantum particle - Psi, thus symbolizing the company's fundamental goal to contribute in India's goal to be the leader in the Quantum realm and also become a global leader in Quantum paradigm shift in coming years.
- Willow Wealth — Willow Wealth is an alternative investment platform focused on generating income streams for investors. Get exclusive access to private market investments.
- Hubble Network — Connect a Bluetooth device to a global satellite network, delivering affordable, low-power tracking and monitoring for diverse industrial and commercial applications.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 583
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
- FINE Legal — fine. holt Dir Dein Geld einfach, digital und ohne Risiko.
- NAVAN Technologies — NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yetgentle and non-perturbative manne
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 161
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $14M–$146M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Septerna — Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors
- NinePoint Medical — NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners.
- Jounce Therapeutics — Concentra is a biosciences company.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 217
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 183
- Round size: Series A $13M–$70M; Series B $16M–$110M; Series C $14M–$120M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $450M in 2022
Portfolio highlights
- Skye Bioscience — Skye Bioscience is a pharmaceutical company providing new therapeutic outcomes for diseases with significant prevalence and unmet needs. It develops proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions.
- Enliven Therapeutics — Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectivelydevelop precision oncology therapeutics that enhance overall patient well-being.Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado.
- Magnetic Insight — Magnetic Insight (MI) introduced magnetic particle imaging into the preclinical diagnostic research market enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 227
- Round size: Series A $9M–$84M; Series B $20M–$125M; Series C $12M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $850M in 2021
Portfolio highlights
- Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
- Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
- Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Pre-Seed
- Geography: United States, Argentina, United Kingdom
Investor stats
- Total investments: 252
- Round size: Seed $50k–$1.7M; Pre-Seed $25k–$1.3M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
- Insignum AgTech — Insignum AgTech develops biotech plants that communicate with producers, alerting them to an illness in its early stages.
- Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 198
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Gyroscope Therapeutics — Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatmentdelivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 135
- Round size: Seed $458k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Hexigone Inhibitors — Hexigone aims to replace toxic chemicals used in the anti-corrosion market with our disruptive, novel, micro/nano reservoir technologies, creating 'smart' coatings. Our additives will enable the coatings to protect for longer in an intelligent manner, increasing the lifetime cycle of the end product, reducing the drain on primaryresources.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 217
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $29M–$283M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Tmunity Therapeutics — Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen....
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 1759
- Round size: Seed $1.6M–$17M; Series A $9M–$55M; Series B $16M–$112M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Tenfold — Tenfold connects systems of engagement and customer data to enable contextual continuous conversations. Get a free demo today.
- Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
- Matik — Remove the data bottleneck & pull numbers, tables, and charts directly into decks and PDFs
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 100
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 169
- Round size: Series A $10M–$100M; Series B $20M–$123M; Series C $15M–$102M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- VitaDAO — Join VitaDAO, a community owned collective funding early stage longevity research. We fund and commercialize longevity therapeutics.
- Ixchelsis — Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 671
- Round size: Series A $5M–$40M; Series B $8M–$75M; Series C $7.1M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Lev — Save time, get great rates, and eliminate the paperwork on your next commercial real estate loan. Lev gets you financing in as little as 30 days.
- Berkshire Grey — Berkshire Grey develops a materials handling system intended to automate omnichannel fulfillment. Its system utilizes artificial intelligence, computer vision, machine learning, and novel sensing to deploy intelligent robotic systems that automate tasks never before performed by machines in commercial settings, enabling customers to achieve higheraccuracy and throughput speeds than traditional approaches as well as handle the broadest assortment of products, packaging, and parcels with ease.
- GroundWork — GroundWork delivers Unified Monitoring for Real™ with an open software platform for shockingly easy integrations and customized visualizations of cloud, virtualization, network, application, server, and storage data.GroundWork Monitor is available in free (Core) and subscription versions with support (Enterprise).GroundWork was founded in 2004 andis headquartered in San Francisco, California with partners in Asia Pacific, Europe and South America.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 359
- Round size: Seed $375k–$3.9M; Grant $119k–$4.3M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- KubeNet — We are KubeNet - a multi-award winning technology solutions provider based in Glasgow. Whether it's Managed IT, IT Support, Cloud, Connectivity, Voice or Cyber Security, we're by your side as your trusted technology partner.
- Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 551
- Round size: Seed $1.8M–$30M; Series A $7.3M–$100M; Series B $13M–$193M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2007
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Kyruus Health — Kyruus Health is a care access platform that provides solutions for providers data management, patient engagement, and activation.
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 192
- Round size: Series A $3.7M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
- Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
- AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United States, Canada
Investor stats
- Total investments: 120
- Round size: Seed $350k–$3M; Series A $3M–$40M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — raised $20M in 2002
Portfolio highlights
- Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
- Overwatch Health — Overwatch Health offers an AI-assisted virtual rehab for cardiac and pulmonary patients.
- Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 128
- Round size: Series A $7M–$94M; Series B $6.5M–$175M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Abridge — For patients, clinicians, and enterprise, our audio-based solutions capture the details and summarize medical conversations, anywhere care happens.
- Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
- United States Fund For Unicef — United States Fund For Unicef helps save and protect the world's most vulnerable children.
KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 93
- Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $80M in 2022
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 163
- Round size: Seed $2M–$15M; Series A $8.5M–$40M; Series B $16M–$91M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Onepot.ai — Onepot.ai offers automated synthesis of small molecules from basic building blocks using a unified, end-to-end process. It generates around fifty distinct compounds in a single workflow, eliminating the need for bespoke methods for each target. The platform employs modular couplings, deprotection, and streamlined purification steps to rapidlyassemble structurally diverse molecules. It supports chemistries that produce both sp²- and sp³-rich frameworks, enabling applications across pharmaceutical, materials, and probe development. By leveraging a catch-and-release purification protocol and iterative building-block assembly, Onepot.ai enables efficient production of complex small-molecule libraries.
- Adaption Labs — Adaptation creates AI systems that adjust to changing real-world circumstances.
- Tools For Humanity — Tools for Humanity is a technology company building for humans in the age of AI.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 154
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 277
- Round size: Seed $1.1M–$5M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
- Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
- PredictImmune — Pragmatic play menciptakan demo slot x500 yang merupakan slot online gratis. Nikmati slot demo pragmatic gacor gampang menang di demo pragmatic jamin gacor.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 238
- Round size: Series A $3.1M–$27M; Series B $3.4M–$65M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 391
- Round size: Seed $1.5M–$10M; Series A $5.8M–$45M; Series B $15M–$130M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $1B in 2023
Portfolio highlights
- Agility — Agility develops humanoid robots and automation platforms for warehouse, manufacturing, and logistics operations. It provides robotic deployment solutions and software platforms that support industrial automation and the handling of repetitive tasks. The company also offers software platforms to manage and support robotic operations in industrialenvironments.
- CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
- Tradeshift — Tradeshift is a supply chain network, Tradeshift is a market leader in e-invoicing and accounts payable automation and an innovator in supplier financing and B2B marketplaces.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, France, Switzerland
Investor stats
- Total investments: 217
- Round size: Series A $7.3M–$115M; Series B $15M–$150M; Series C $15M–$94M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $650M in 2016
Portfolio highlights
- Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.
- Vera Therapeutics — Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential. The company's gene-editing technology can potentially cure patients with sickle cell disease, cystic fibrosis, and other devastating genetic disorders, enabling physicians to improve gene detection and regulation.
- Marinus Pharmaceuticals — Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 177
- Round size: Seed $1.3M–$12M; Series A $6.3M–$46M; Series B $13M–$168M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 140
- Round size: Series A $9.2M–$102M; Series B $22M–$120M; Series C $33M–$107M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Peloton Therapeutics — Peloton Therapeutics is translating groundbreaking scientific insights into first-in-class oral medicines to fight cancer and other serious conditions.
- NGM Biopharmaceuticals — Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
- Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 181
- Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 259
- Round size: Seed $300k–$5.3M; Series A $2.4M–$25M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $50M in 2023
Portfolio highlights
- 1touch.io — By continuously analyzing traffic and repository stores connected to your network, our network-based solution can detect all elements on the network that are storing, processing, and sharing personal data, both internally and externally. Whether structured or unstructured data, data in motion or at rest, and even data that is unknown to you,1touch.io can track it for you.
- Emme E2MS — Emme E2MS, LLC provides energy management solutions for the light commercial and residential markets. The company offers Energy and Environmental Management System, a platform that provides environmental controls and detailed energy monitoring solutions; and +Energy that displays electricity consumption in kilowatt/hours, dollars, and bycarbon footprint. It also provides SmartSensors, heating and cooling monitor systems, wireless outdoor temperature sensors, and wireless receivers. The company was incorporated in 2012 and is based in Beaverton, Oregon.
- Mobile Sense — The traditional diagnostic market is being transformed by advances in high performance wearables. This seismic shift led by consumer products which are uncovering new patients who previously went undetected, but still require a detailed diagnosis. Mobile Sense™ is building foundational technology that enables this transformation throughoff-the-chest wearables for long term management of cardiac arrhythmias. Developed over 7 years with $4.2M in grant funding and $1.3M in seed funding, Mobile Sense™ has a platform for differentiated wearables. Our embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provides high fidelity continuous ECG and PPG recordings. The automatic monitoring provides 24/7, 365 days/yr continuous detection and classification of dangerous heart arrhythmias.
Biotechnology Investor funding at a glance
Stats across 31k deals from 18k investors.
Access all 17645 investors in Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 17645 investors investing in Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!